Company news

Longeveron Inc. news in 2021

Longeveron Inc.'s news releases, calls and decks from 2021, newest first.

View company

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

December 5, 2021

Longeveron Inc. Announces Closing of a $20.5 Million Private Placement

December 2, 2021

Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement

November 30, 2021

Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

November 29, 2021

U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

November 17, 2021

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 11, 2021

Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021

November 7, 2021

Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

November 4, 2021

Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)

October 19, 2021

Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity

September 28, 2021

Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research

September 27, 2021

Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research

September 20, 2021

Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy

September 12, 2021

Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients

September 8, 2021

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 12, 2021

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

August 12, 2021

Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021

August 9, 2021

Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study

July 5, 2021

Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference

June 23, 2021

Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors

May 24, 2021

Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs

May 17, 2021

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 13, 2021

Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021

May 10, 2021

Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination

April 14, 2021

Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease

April 12, 2021

Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

March 29, 2021

Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call

March 25, 2021

Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

March 14, 2021

Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)

March 10, 2021

Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations

March 9, 2021

Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection

March 4, 2021

Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty

March 2, 2021

Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients

February 23, 2021

Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors

February 17, 2021

Longeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing

February 10, 2021

Calls in 2021

Decks in 2021